COVID antibody trial for kids halted after just 2 patients
NCT ID NCT05092581
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 30 times
Summary
This study tested a single dose of two lab-made antibodies (casirivimab+imdevimab) given through a vein to children hospitalized with COVID-19. The goal was to see how the drug moves in the body and if it is safe. Only 2 children took part before the study was stopped early, so results are very limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Le Bonheur Children's Hospital
Memphis, Tennessee, 38103, United States
-
State University of New York at Stony Brook
Stony Brook, New York, 11794, United States
Conditions
Explore the condition pages connected to this study.